Bausch + Lomb (BLCO) shifts board chair, adds new committee leaders
Rhea-AI Filing Summary
Bausch + Lomb Corporation reports updates to its board leadership and committee assignments effective August 10, 2026. Thomas J. Appio has succeeded Brent Saunders as Chairman of the Board, while Mr. Saunders continues to serve as a director. The board has also appointed Laurence Paul, M.D. as Lead Independent Director.
On the same date, Robert Chersi joined the Audit and Risk Committee and the Talent and Compensation Committee. Dr. Paul joined the Nominating and Corporate Governance Committee and the Science and Technology Committee. John A. Paulson was named chair of the Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. as chair of the Science and Technology Committee, and Barbara Trebbi as chair of the Talent and Compensation Committee.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective date of leadership changes: August 10, 2026
Initial 8-K filing date referenced: August 6, 2026
Effective date of new director appointments: August 5, 2026
3 metrics
Effective date of leadership changes
August 10, 2026
Date when Appio became Chairman and committee appointments took effect
Initial 8-K filing date referenced
August 6, 2026
Date of the earlier report describing resignations and initial appointments
Effective date of new director appointments
August 5, 2026
Date when Appio, Chersi, Paul and Trebbi were appointed to the board
Key Terms
Lead Independent Director, Audit and Risk Committee, Talent and Compensation Committee, Nominating and Corporate Governance Committee, +1 more
5 terms
Lead Independent Director financial
"the Board has also appointed Dr. Paul to serve as Lead Independent Director"
A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.
Audit and Risk Committee financial
"the Board appointed Mr. Chersi as a member of its Audit and Risk Committee"
A board committee that oversees a company’s financial reporting, internal controls, compliance and major business risks, and coordinates with external auditors. It acts like a building inspector and alarm system for investors, checking that the company’s books are accurate, controls are working, and potential threats (financial, legal or operational) are identified and managed, which helps protect shareholder value and reduces the chance of surprises.
Talent and Compensation Committee financial
"Mr. Chersi as a member of its Audit and Risk Committee and Talent and Compensation Committee"
Nominating and Corporate Governance Committee financial
"Dr. Paul as a member of its Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Science and Technology Committee technical
"Eduardo Alfonso, M.D. as chair of its Science and Technology Committee"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What leadership change did Bausch + Lomb (BLCO) announce on August 10, 2026?
Bausch + Lomb announced that Thomas J. Appio succeeded Brent Saunders as Chairman of the Board effective August 10, 2026. Mr. Saunders will continue to serve as a member of the board after this leadership transition.
Who is the new Lead Independent Director at Bausch + Lomb (BLCO)?
As of August 10, 2026, Laurence Paul, M.D. has been appointed Lead Independent Director. He also joined the Nominating and Corporate Governance Committee and the Science and Technology Committee of the company’s board.
Which board committees did Robert Chersi join at Bausch + Lomb (BLCO)?
Effective August 10, 2026, Robert Chersi was appointed to the board’s Audit and Risk Committee and its Talent and Compensation Committee. These roles expand his responsibilities in financial oversight and executive compensation matters.
Who chairs the key Bausch + Lomb (BLCO) board committees after the August 2026 changes?
John A. Paulson now chairs the Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. chairs the Science and Technology Committee, and Barbara Trebbi chairs the Talent and Compensation Committee, all effective August 10, 2026.
Does Brent Saunders remain on the Bausch + Lomb (BLCO) board after stepping down as Chairman?
Yes. Although Brent Saunders was succeeded by Thomas J. Appio as Chairman of the Board on August 10, 2026, he continues to serve as a member of the Bausch + Lomb board of directors.